Bristol Myers Squibb Partners with Ex-Soccer Star Kasey Keller to Promote CAR T-Cell Therapy Breyanzi
Event summary
- Bristol Myers Squibb collaborates with former soccer star Kasey Keller to share his lymphoma treatment journey with Breyanzi, a CAR T-cell therapy.
- Keller, diagnosed with non-Hodgkin lymphoma in 2010, underwent multiple treatments before finding success with Breyanzi.
- The partnership launches on World Cancer Day to raise awareness about CAR T-cell therapy and its potential to cure blood cancers.
- Breyanzi reduced the risk of events by 62% at a 3-year follow-up compared to standard care.
The big picture
Bristol Myers Squibb’s collaboration with Kasey Keller underscores the strategic importance of patient advocacy in driving awareness for advanced therapies like Breyanzi. The partnership aligns with broader industry trends of leveraging high-profile figures to demystify complex treatments and address logistical barriers that prevent eligible patients from accessing CAR T-cell therapies. With Breyanzi already approved for multiple indications, this initiative could further solidify Bristol Myers Squibb’s leadership in cell therapy.
What we're watching
- Patient Awareness
- Whether Kasey Keller’s story can significantly increase patient awareness and adoption of Breyanzi.
- Therapeutic Reach
- The pace at which Bristol Myers Squibb can expand Breyanzi’s reach to more eligible patients.
- Market Dynamics
- How this partnership positions Bristol Myers Squibb in the competitive landscape of CAR T-cell therapies.
Related topics